These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 20184539)
1. Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia. Chen Y; Peng C; Sullivan C; Li D; Li S Anticancer Agents Med Chem; 2010 Feb; 10(2):111-5. PubMed ID: 20184539 [TBL] [Abstract][Full Text] [Related]
2. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Chen Y; Hu Y; Michaels S; Segal D; Brown D; Li S Leukemia; 2009 Aug; 23(8):1446-54. PubMed ID: 19322212 [TBL] [Abstract][Full Text] [Related]
3. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells. Wu L; Yu J; Chen R; Liu Y; Lou L; Wu Y; Huang L; Fan Y; Gao P; Huang M; Wu Y; Chen Y; Xu J Clin Cancer Res; 2015 Feb; 21(4):833-43. PubMed ID: 25501124 [TBL] [Abstract][Full Text] [Related]
4. The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia. Chen Y; Li D; Li S Cell Cycle; 2009 Nov; 8(21):3488-92. PubMed ID: 19823023 [TBL] [Abstract][Full Text] [Related]
5. Characterization of cancer stem cells in chronic myeloid leukaemia. Jørgensen HG; Holyoake TL Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348 [TBL] [Abstract][Full Text] [Related]
6. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells. Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012 [TBL] [Abstract][Full Text] [Related]
9. Omacetaxine mepesuccinate in chronic myeloid leukemia. Al Ustwani O; Griffiths EA; Wang ES; Wetzler M Expert Opin Pharmacother; 2014 Nov; 15(16):2397-405. PubMed ID: 25301179 [TBL] [Abstract][Full Text] [Related]
10. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia. Jin Y; Zhou J; Xu F; Jin B; Cui L; Wang Y; Du X; Li J; Li P; Ren R; Pan J J Clin Invest; 2016 Oct; 126(10):3961-3980. PubMed ID: 27643437 [TBL] [Abstract][Full Text] [Related]
11. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Hu Y; Chen Y; Douglas L; Li S Leukemia; 2009 Jan; 23(1):109-16. PubMed ID: 18818703 [TBL] [Abstract][Full Text] [Related]
12. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia. Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353 [TBL] [Abstract][Full Text] [Related]
13. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells. Scappini B; Onida F; Kantarjian HM; Dong L; Verstovsek S; Keating MJ; Beran M Cancer; 2002 May; 94(10):2653-62. PubMed ID: 12173333 [TBL] [Abstract][Full Text] [Related]
14. Omacetaxine as an anticancer therapeutic: what is old is new again. Wetzler M; Segal D Curr Pharm Des; 2011; 17(1):59-64. PubMed ID: 21294709 [TBL] [Abstract][Full Text] [Related]
15. Targeted therapy of chronic myeloid leukemia. Sullivan C; Peng C; Chen Y; Li D; Li S Biochem Pharmacol; 2010 Sep; 80(5):584-91. PubMed ID: 20470758 [TBL] [Abstract][Full Text] [Related]
17. Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro. Liu MY; Wang WZ; Liao FF; Wu QQ; Lin XH; Chen YH; Cheng L; Jin XB; Zhu JY Cell Biol Int; 2017 Jan; 41(1):16-23. PubMed ID: 27677634 [TBL] [Abstract][Full Text] [Related]
18. Antitumor Effects of Blocking Protein Neddylation in T315I-BCR-ABL Leukemia Cells and Leukemia Stem Cells. Liu C; Nie D; Li J; Du X; Lu Y; Li Y; Zhou J; Jin Y; Pan J Cancer Res; 2018 Mar; 78(6):1522-1536. PubMed ID: 29321163 [TBL] [Abstract][Full Text] [Related]
19. Depletion of γ-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with Imatinib. Jin Y; Yao Y; Chen L; Zhu X; Jin B; Shen Y; Li J; Du X; Lu Y; Jiang S; Pan J Theranostics; 2016; 6(11):1947-62. PubMed ID: 27570562 [TBL] [Abstract][Full Text] [Related]